From Nasdaq, Inc.: 2025-04-18 16:07:00

Validea’s guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN) shows that it rates highest using the Value Investor model based on Benjamin Graham’s strategy. The stock is a large-cap value stock in the Biotechnology & Drugs industry, with a rating of 71% based on fundamentals and valuation. The strategy looks for low P/B and P/E ratios, low debt, and solid long-term earnings growth. While the stock passes some criteria like sales and current ratio, it fails the P/E ratio and price/book ratio tests. Benjamin Graham, known as the “Father of Value Investing,” has had a lasting impact on the investing world.



Read more at Nasdaq, Inc.: Benjamin Graham Detailed Fundamental Analysis – REGN